RxDoctor Payments Data

Nicole Stover

Family · Clearfield, PANPI 1609529312

Payments from drug & device makers

$1,480in general payments, 2019–2025

Across 83 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$360
  • Pfizer$216
  • GSK$125
  • Novo Nordisk$113
  • AbbVie$112
  • Phathom Pharmaceuticals, Inc.$83
  • plus $471 from 14 others

What the payments were for

  • Food & beverage$1,480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,480 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$105,761
Medicare patients
280
Services billed
2,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$80,644
TrulicityDulaglutide25$32,065
TradjentaLinagliptin24$25,448
OzempicSemaglutide24$22,015
MyrbetriqMirabegron26$20,277
EntrestoSacubitril/Valsartan24$19,647
JardianceEmpagliflozin13$10,265
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,976
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$8,397
Tresiba Flextouch U-100Insulin Degludec19$7,727
Breo ElliptaFluticasone/Vilanterol11$6,858
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,056
Levothyroxine Sodium367$3,815
Potassium Chloride115$3,435
SymbicortBudesonide/Formoterol Fumarate11$3,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$216$80,64495 claims
Lilly USA, LLCTrulicity$40$32,06525 claims
Novo NordiskOzempic$113$22,01524 claims
GSKTrelegy Ellipta, Breo Ellipta$125$15,83425 claims
AstraZenecaSymbicort$68$3,34711 claims
AbbVieSynthroid$112$1,10326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Clearfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →